PMID- 27713123 OWN - NLM STAT- MEDLINE DCOM- 20180226 LR - 20231104 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 47 DP - 2016 Nov 22 TI - Abnormal amphiregulin expression correlates with gastric cancer prognosis. PG - 76684-76692 LID - 10.18632/oncotarget.12436 [doi] AB - Gastric cancer (GC) is a global health issue with a high mortality rate. Early diagnosis and tracking of GC is a challenge due to a lack of reliable tools. Amphiregulin (AREG) is a member of the epidermal growth factor (EGF) family that activates growth signaling upon binding of EGF receptors. Elevated AREG expression is associated with various pathological conditions, including cancer. Here, we investigated whether increased AREG expression is a disease indicator and/or prognostic biomarker for GC. We used tissue microarray and quantitative real-time polymerase chain reaction to assess AREG expression in clinical tissue specimens at various stages of GC and a conducted bioinformatics analysis to evaluate the value of AREG over-expression as a GC biomarker. We found that both mRNA and protein expression of AREG were increased in the tissues of GC patients when compared to tissues from non-cancer patients or normal tissues. High expression of AREG was also associated with GC clinicopathological characteristics and poor survival. Thus, over-expression of AREG could serve as a novel GC biomarker, and active surveillance of its expression could be a novel approach to GC diagnosis and monitoring. FAU - Wang, Bing AU - Wang B AD - Center for Pathology and Laboratory Medicine, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China. AD - Department of Oncology, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China. FAU - Yong, Hongmei AU - Yong H AD - Department of Oncology, Huai'an Hospital Affiliated of Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, Jiangsu, China. FAU - Zhu, Huijun AU - Zhu H AD - Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China. FAU - Ni, Daguang AU - Ni D AD - Center for Pathology and Laboratory Medicine, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China. FAU - Tang, Sijie AU - Tang S AD - Center for Pathology and Laboratory Medicine, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China. FAU - Zhang, Shu AU - Zhang S AD - Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China. FAU - Wang, Wei AU - Wang W AD - Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China. FAU - Zhou, Yan AU - Zhou Y AD - Department of Oncology, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China. FAU - Zhao, Wei AU - Zhao W AD - Department of Pathology, Nanjing Medical University, Nanjing, China. FAU - Ding, Guipeng AU - Ding G AD - Department of Pathology, Nanjing Medical University, Nanjing, China. FAU - Zhu, Jin AU - Zhu J AD - Huadong Medical Institute of Biotechniques, Nanjing, China. FAU - Li, Xiaohua AU - Li X AD - Center for Pathology and Laboratory Medicine, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China. AD - School of Medicine, Jiangsu University, Jiangsu, China. AD - The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Feng, Zhenqing AU - Feng Z AD - Department of Oncology, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China. AD - Department of Pathology, Nanjing Medical University, Nanjing, China. AD - Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, Nanjing, China. AD - Jiangsu Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Amphiregulin) RN - 0 (Biomarkers, Tumor) RN - 0 (RNA, Messenger) SB - IM MH - Adult MH - Aged MH - Amphiregulin/*genetics MH - *Biomarkers, Tumor MH - Female MH - *Gene Expression MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - RNA, Messenger/genetics/metabolism MH - Stomach Neoplasms/*genetics/*mortality/pathology MH - Survival Analysis PMC - PMC5363540 OTO - NOTNLM OT - amphiregulin OT - gastric cancer OT - prognosis COIS- CONFLICTS OF INTEREST None. EDAT- 2016/10/08 06:00 MHDA- 2018/02/27 06:00 PMCR- 2016/11/22 CRDT- 2016/10/08 06:00 PHST- 2016/04/05 00:00 [received] PHST- 2016/09/27 00:00 [accepted] PHST- 2016/10/08 06:00 [pubmed] PHST- 2018/02/27 06:00 [medline] PHST- 2016/10/08 06:00 [entrez] PHST- 2016/11/22 00:00 [pmc-release] AID - 12436 [pii] AID - 10.18632/oncotarget.12436 [doi] PST - ppublish SO - Oncotarget. 2016 Nov 22;7(47):76684-76692. doi: 10.18632/oncotarget.12436.